Global and U.S. Prefilled Autoinjectors Market Report, Published by QY Research.

QY Research has released a comprehensive new market report on Prefilled Autoinjectors, advanced drug-delivery devices designed to automatically administer a premeasured dose of medication through subcutaneous or intramuscular injection. Combining a prefilled syringe or cartridge with a spring- or motor-driven injection mechanism, prefilled autoinjectors enable safe, accurate, and user-friendly self-administration of biologics, vaccines, hormones, and emergency medicines. As healthcare systems shift toward home-based care, biologics expansion, and patient-centric delivery, this report provides an in-depth assessment of global market size, device innovation, regulatory dynamics, and competitive landscape.

Core Market Data

Global market size: USD 4.7 billion
CAGR (2024-2030): 11.4%
Average price: USD 15 per unit
Annual production: 310 million units
Gross margin: 42%
Production capacity: 380 million units

List of Main Players

BD & Company (NYSE: BDX, USA)
Gerresheimer (FRA: GXI, Germany)
Stevanato (NYSE: STVN, Italy)
Nipro Medical (TYO: 8086, Japan)
Antares Pharma (NASDAQ: ATRS, USA)
Insulet (NASDAQ: PODD, USA)
West Pharma (NYSE: WST, USA)
AptarGroup (NYSE: ATR, USA)
Pfizer (NYSE: PFE, USA)
Sanofi (EPA: SAN, France)
Amgen (NASDAQ: AMGN, USA)
Teva Pharma (NYSE: TEVA, Israel)
SCHOTT (Private, Germany)
Catalent (Private, USA)
Vetter Pharma (Private, Germany)
Nemera (Private, France)
Haselmeier (Private, Germany)
Owen Mumford (Private, UK)
SHL Medical (Private, Switzerland)
Ypsomed (Public, Switzerland)
ApiJect Systems (Private, USA)
Enable Injections (Private, USA)
Kindeva Drug Delivery (Private, USA)

1. By Injection Mechanism

Spring-powered
Gas-powered
Motor-driven

2. By Drug Volume

Single-dose Autoinjectors
Dual-dose Autoinjectors
Multi-dose Autoinjectors

3. By Therapeutic Area

Subcutaneous Injection
Intramuscular Injection

4. By End User

Home self-administration
Hospitals and clinics
Emergency medical services
Specialty pharmacies

Case Study for Bidding

Time: May 2024
Supplier: Ypsomed
Buyer: Amgen
Product: Prefilled, spring-driven autoinjectors for monoclonal antibody therapy
Quantity: 120 million units
Contract Value: USD 620 million
Delivery Timeline: January 2026

Case Study for End Using

End User: Sanofi

Application: Home-based self-administration of biologic therapy for autoimmune disease patients.

Installation Location / Usage Stage

Supplied as ready-to-use, single-dose disposable devices.
Stored under refrigerated conditions and activated at point of use.
Designed for patient self-injection with minimal training.

Purpose

Ensures accurate and consistent drug dosing.
Reduces injection anxiety and user error.
Enables decentralized, home-based treatment.

Effect

Improved patient adherence by 30%+.
Reduced clinic visits and healthcare burden.
Enhanced patient satisfaction and treatment continuity.

Alternative Drug-Delivery Methods
Prefilled syringes are lower cost but require manual injection skill.
Wearable injectors handle large volumes but increase device complexity and cost.
Oral biologics improve convenience but remain limited by bioavailability challenges.

Therefore, Prefilled Autoinjectors have become a cornerstone of modern drug delivery, enabling safe, scalable, and patient-friendly administration of advanced therapies across chronic, emergency, and specialty care.

About QY Research

QY Research has established close partnerships with over 71,000 global leading players. With more than 20,000 industry experts worldwide, we maintain a strong global network to efficiently gather insights and raw data.

Our 36-step verification system ensures the reliability and quality of our data. With over 2 million reports, we have become the world's largest market report vendor. Our global database spans more than 2,000 sources and covers data from most countries, including import and export details.

We have partners in over 160 countries, providing comprehensive coverage of both sales and research networks. A 90% client return rate and long-term cooperation with key partners demonstrate the high level of service and quality QY Research delivers.

More than 30 IPOs and over 5,000 global media outlets and major corporations have used our data, solidifying QY Research as a global leader in data supply. We are committed to delivering services that exceed both client and societal expectations.

For Inquiries:

USA: +1-626-295-2442

Canada: +1-778-907-6631

China: +86-150-1303-8387

Japan: +81-90-3800-9273

South Korea: +82-2883-1278

India: +91-866-9986-909

Indonesia: +62-818-510-991

Germany: +49-15788468916

Switzerland: +41-765899438

Portugal: +351-910983247

Email: global@qyresearch.com

www.qyresearch.com

This release was published on openPR.